Amplification and overexpression of CMET is a common event in brain metastases of non-small cell lung cancer.

Abstract

BACKGROUND CMET represents an emerging therapy target for monoclonal antibodies and tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC). METHODS We investigated CMET gene amplification status by fluorescence in-situ hybridization (FISH) and CMET protein expression by immunohistochemistry in a large series of 209 NSCLC brain metastases (BM… (More)
DOI: 10.1111/his.12475

Topics

Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.